The University of Southampton
University of Southampton Institutional Repository

European Biological Variation Study (EuBIVAS): within and between-subject biological variation estimates of β-isomerized C-terminal telopeptide of type I collagen (β-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein—a cooperation between the EFLM Working Group on Biological Variation and the International Osteoporosis Foundation-International Federation of Clinical Chemistry Committee on Bone Metabolism

European Biological Variation Study (EuBIVAS): within and between-subject biological variation estimates of β-isomerized C-terminal telopeptide of type I collagen (β-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein—a cooperation between the EFLM Working Group on Biological Variation and the International Osteoporosis Foundation-International Federation of Clinical Chemistry Committee on Bone Metabolism
European Biological Variation Study (EuBIVAS): within and between-subject biological variation estimates of β-isomerized C-terminal telopeptide of type I collagen (β-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein—a cooperation between the EFLM Working Group on Biological Variation and the International Osteoporosis Foundation-International Federation of Clinical Chemistry Committee on Bone Metabolism

Summary: We have calculated the biological variation (BV) of different bone metabolism biomarkers on a large, well-described cohort of subjects. BV is important to calculate reference change value (or least significant change) which allows evaluating if the difference observed between two consecutive measurements in a patient is biologically significant or not. Introduction: Within-subject (CV I) and between-subject (CV G) biological variation (BV) estimates are essential in determining both analytical performance specifications (APS) and reference change values (RCV). Previously published estimates of BV for bone metabolism biomarkers are generally not compliant with the most up-to-date quality criteria for BV studies. We calculated the BV and RCV for different bone metabolism markers, namely β-isomerized C-terminal telopeptide of type I collagen (β-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin (OC), intact fibroblast growth factor 23 (iFGF-23), and uncarboxylated-unphosphorylated Matrix-Gla Protein (uCuP-MGP) using samples from the European Biological Variation Study (EuBIVAS). Methods: In the EuBIVAS, 91 subjects were recruited from six European laboratories. Fasting blood samples were obtained weekly for ten consecutive weeks. The samples were run in duplicate on IDS iSYS or DiaSorin Liaison instruments. The results were subjected to outlier and variance homogeneity analysis before CV-ANOVA was used to obtain the BV estimates. Results: We found no effect of gender upon the CV I estimates. The following CV I estimates with 95% confidence intervals (95% CI) were obtained: β-CTX 15.1% (14.4–16.0%), PINP 8.8% (8.4–9.3%), OC 8.9% (8.5–9.4%), iFGF23 13.9% (13.2–14.7%), and uCuP-MGP 6.9% (6.1–7.3%). Conclusions: The EuBIVAS has provided updated BV estimates for bone markers, including iFGF23, which have not been previously published, facilitating the improved follow-up of patients being treated for metabolic bone disease.

Biological variation, Bone markers, CTX, FGF23, MGP, Osteocalcin, PINP, Reference change value
0937-941X
1461-1470
Cavalier, Etienne
bc312308-1b70-4434-ab15-28860479d2e9
Lukas, P.
b3d1aac2-ef31-44eb-b01f-78ae61e38ae7
Bottani, M.
03a97f46-6417-4515-b53d-3ac2ae791846
Aarsand, A.K.
cdd19cbd-b6ba-451b-8cee-640dcbf89beb
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Ceriotti, F.
1c87eabf-8675-4c0f-bb09-f6b0cc077a2d
Cavalier, Etienne
bc312308-1b70-4434-ab15-28860479d2e9
Lukas, P.
b3d1aac2-ef31-44eb-b01f-78ae61e38ae7
Bottani, M.
03a97f46-6417-4515-b53d-3ac2ae791846
Aarsand, A.K.
cdd19cbd-b6ba-451b-8cee-640dcbf89beb
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Ceriotti, F.
1c87eabf-8675-4c0f-bb09-f6b0cc077a2d

Cavalier, Etienne, Lukas, P., Bottani, M., Aarsand, A.K., Cooper, Cyrus and Ceriotti, F. (2020) European Biological Variation Study (EuBIVAS): within and between-subject biological variation estimates of β-isomerized C-terminal telopeptide of type I collagen (β-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein—a cooperation between the EFLM Working Group on Biological Variation and the International Osteoporosis Foundation-International Federation of Clinical Chemistry Committee on Bone Metabolism. Osteoporosis International, 31 (8), 1461-1470. (doi:10.1007/s00198-020-05362-8).

Record type: Article

Abstract

Summary: We have calculated the biological variation (BV) of different bone metabolism biomarkers on a large, well-described cohort of subjects. BV is important to calculate reference change value (or least significant change) which allows evaluating if the difference observed between two consecutive measurements in a patient is biologically significant or not. Introduction: Within-subject (CV I) and between-subject (CV G) biological variation (BV) estimates are essential in determining both analytical performance specifications (APS) and reference change values (RCV). Previously published estimates of BV for bone metabolism biomarkers are generally not compliant with the most up-to-date quality criteria for BV studies. We calculated the BV and RCV for different bone metabolism markers, namely β-isomerized C-terminal telopeptide of type I collagen (β-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin (OC), intact fibroblast growth factor 23 (iFGF-23), and uncarboxylated-unphosphorylated Matrix-Gla Protein (uCuP-MGP) using samples from the European Biological Variation Study (EuBIVAS). Methods: In the EuBIVAS, 91 subjects were recruited from six European laboratories. Fasting blood samples were obtained weekly for ten consecutive weeks. The samples were run in duplicate on IDS iSYS or DiaSorin Liaison instruments. The results were subjected to outlier and variance homogeneity analysis before CV-ANOVA was used to obtain the BV estimates. Results: We found no effect of gender upon the CV I estimates. The following CV I estimates with 95% confidence intervals (95% CI) were obtained: β-CTX 15.1% (14.4–16.0%), PINP 8.8% (8.4–9.3%), OC 8.9% (8.5–9.4%), iFGF23 13.9% (13.2–14.7%), and uCuP-MGP 6.9% (6.1–7.3%). Conclusions: The EuBIVAS has provided updated BV estimates for bone markers, including iFGF23, which have not been previously published, facilitating the improved follow-up of patients being treated for metabolic bone disease.

This record has no associated files available for download.

More information

Accepted/In Press date: 19 February 2020
e-pub ahead of print date: 8 April 2020
Published date: 1 August 2020
Additional Information: Funding Information: The authors would like to thank IDS and DiaSorin for providing the reagents and all study participants and other EuBIVAS partners for their essential contribution to the project: Gerhard Barla, Bill Bartlett, Giulia Cajano, Niels Jonker, Mario Plebani, Thomas R?raas, Una ?rvim S?lvik, Marit Sverresdotter Sylte, Mustafa Serteser, Francesca Tosato, and Ibrahim Unsal; the International Osteoporosis Foundation for endorsing the paper; the Members of the IOF-IFCC Committee on Bone Metabolism who have critically read and improved the paper: Kristina ?kesson (Lund, Sweden), Harjit Pal Bhattoa (Debrecen, Hungary), Olivier Bruy?re (Li?ge, Belgium), Cyrus Cooper (Southampton, UK), Richard Eastell (Sheffield, UK), Patrick Garnero (Lyon, France), Annemieke Heijboer (Amsterdam, The Netherlands), Niklas Rye Jorgensen (Copenhagen, Denmark), John Kanis (Sheffield, UK), Konstantinos Makris (Athens, Greece), Candice Z. Ulmer (Atlanta, USA), and Samuel Vasikaran (Murdoch, Australia); as well as the IFCC Scientific Division Executive Committee. Publisher Copyright: © 2020, International Osteoporosis Foundation and National Osteoporosis Foundation.
Keywords: Biological variation, Bone markers, CTX, FGF23, MGP, Osteocalcin, PINP, Reference change value

Identifiers

Local EPrints ID: 441710
URI: http://eprints.soton.ac.uk/id/eprint/441710
ISSN: 0937-941X
PURE UUID: 3abc997c-4dea-4c9c-868e-44dc0c42aefa
ORCID for Cyrus Cooper: ORCID iD orcid.org/0000-0003-3510-0709

Catalogue record

Date deposited: 24 Jun 2020 16:30
Last modified: 18 Mar 2024 02:46

Export record

Altmetrics

Contributors

Author: Etienne Cavalier
Author: P. Lukas
Author: M. Bottani
Author: A.K. Aarsand
Author: Cyrus Cooper ORCID iD
Author: F. Ceriotti

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×